Investigations of pharmaceutical compounds co-crystallization for application to chiral resolution assisted by supercritical CO2

Abstract

Co-crystalline products are becoming increasingly important in the pharmaceutical industry, due to the chirality, low water solubility and low bioavailability of most active pharmaceutical ingredients (API). Solids with a single crystalline phase composed of two entities (API + coformer COF) linked via non-covalent interactions are called co-crystals. The modification of the API crystal lattice through the incorporation of the COF enhances the physicochemical properties of the initial drug without altering its therapeutic purposes. Thus, understanding crystallization processes can help to obtain products with desired properties. The formation of metastable conglomerates by co-crystallization can be a solution for optical resolutionApport du CO2 dans le contrôle de phase cristallin